Catalent Appoints New Vice President and General Manager for European Softgel Business
![](/46/pdcnewsitem/03/30/87/ThRDsXq0l5xACvU.png)
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has appointed Robert Beland to the newly created role of Vice President & General Manger of Softgel Technologies in Europe.
Mr Beland’s main focus will be on leading initiatives that accelerate overall growth within the European region, working closely with other members of the Softgel Leadership Team to refine and execute strategy, strengthen business development and commercial activities, while extending Catalent’s best in class development and manufacturing capabilities. He will be based at Catalent’s Cham, Switzerland office.
An executive leader, with more than 25 years’ experience in the services industry, both in the pharma and the vitamins, minerals, and supplements (VMS) space, Mr. Beland’s professional career includes 2 years at Catalent’s St Petersburg, Florida facility as Vice President and General Manager for Nutritionals. In his extensive career he has led European and North American businesses. Most recently, Mr Beland was Executive Vice President and Chief Operating Officer for Ricerca Biosciences.
“Robert’s appointment will help to further strengthen our leadership position in the European softgel market,” commented Dr Aris Gennadios, Catalent’s President of Softgel Technologies. “He will particularly focus on driving commercialisation of our recently launched new technologies across the Rx, consumer health and skin care segments, and coordinating our R&D and supply capabilities at our European sites in France, Germany and Italy.”
Mr Beland holds a bachelor’s degree in Chemistry from Université de Montréal, Montréal, QC, Canada and a degree in health sciences from Collège Jean-de Brébeuf, Outremont, QC, Canada.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance